Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/13/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Stephan A. Grupp

Wrong Dr. Stephan A. Grupp?

Director of Translational Researc...

The Children's Hospital of Philadelphia
34Th Street And Civic Center Boulevard
Philadelphia, Pennsylvania 19104
United States

Company Description: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • M.D.
  • Ph.D.
  • MD
  • PhD
118 Total References
Web References
Board of Trustees | Aspho.org
www.aspho.org, 13 Feb 2014 [cached]
Stephan Grupp, MD PhD Children's Hospital of Philadelphia
Pediatric oncologist Stephan A. ...
www.sys-con.com, 8 Dec 2013 [cached]
Pediatric oncologist Stephan A. Grupp, M.D., Ph.D., of The Children's Hospital of Philadelphia and a Professor of Pediatrics at the Perelman School of Medicine of the University of Pennsylvania, presented outcomes and follow-up results of this immunotherapy clinical trial for pediatric and adult patients with ALL in a press program today at the annual meeting of the American Society of Hematology (ASH) in New Orleans.
...
Grupp presented alongside Penn investigator Michael Kalos, Ph.D., during the press program.
...
The current study reflects an ongoing collaboration between Grupp and the Penn Medicine scientists who originally developed this personalized cell therapy as a treatment for adult patients with CLL, another B-cell leukemia.
...
We are looking forward to testing these cells in upcoming multicenter pediatric and adult trials," said Grupp.
In August 2012, Novartis acquired exclusive rights from Penn to CTL019. Several authors from Novartis are co-authors of the abstracts presented by Grupp and others at the ASH meeting.
Note to Reporters: For interviews with Stephan Grupp, M.D., Ph.D., regarding pediatric patients in these studies, please contact Rachel Salis-Silverman, cell: 267-970-3685; salis@email.chop.edu.
...
Stephan Grupp, MD, PhD, pediatric oncologist and director of Translational Research at The Children's Hospital of Philadelphia Cancer Center
IMAGE: Stephan Grupp, M.D., ...
www.eurekalert.org, 7 Dec 2013 [cached]
IMAGE: Stephan Grupp, M.D., Ph.D., is a pediatric oncologist and director of Translational Research at The Children's Hospital of Philadelphia Cancer Center. Click here for more information.
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children's Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
Pediatric oncologist Stephan A. Grupp, M.D., Ph.D., of The Children's Hospital of Philadelphia and a Professor of Pediatrics at the Perelman School of Medicine of the University of Pennsylvania, presented outcomes and follow-up results of this immunotherapy clinical trial for pediatric and adult patients with ALL in a press program today at the annual meeting of the American Society of Hematology (ASH) in New Orleans.
...
Grupp presented alongside Penn investigator Michael Kalos, Ph.D., during the press program.
...
The current study reflects an ongoing collaboration between Grupp and the Penn Medicine scientists who originally developed this personalized cell therapy as a treatment for adult patients with CLL, another B-cell leukemia.
...
We are looking forward to testing these cells in upcoming multicenter pediatric and adult trials," said Grupp.
###
In August 2012, Novartis acquired exclusive rights from Penn to CTL019. Several authors from Novartis are co-authors of the abstracts presented by Grupp and others at the ASH meeting.
Both had been treated and had ...
www.berkshireeagle.com, 10 Dec 2012 [cached]
Both had been treated and had then relapsed, said Stephan Grupp, director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia. He presented research on their care at the hematology meeting.
One of the girls has been in complete remission in the eight months since her treatment. The other had a remission of "a few months" before relapsing again, Grupp said. The younger girl had severe side-effects.
Previous studies have documented severe, flu-like illness in patients treated with their pumped-up immune cells. The 7-year-old's severe reaction helped explain what was happening, Grupp said. Her levels of an inflammatory protein called IL-6 were very high, 998 times her ordinary level. His group treated her with Roche's Actemra, approved for rheumatoid arthritis, which targets the protein. Because her levels of another inflammatory protein called TNF were high, she was also treated with Amgen and Pfizer's Enbrel.
"The next morning, she was dramatically better," Grupp said.
"Our results serve as another important ...
www.prnewswire.com, 7 Dec 2013 [cached]
"Our results serve as another important milestone in demonstrating the potential of this treatment for patients who truly have no other therapeutic options," said study author Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. "These data also demonstrate that these engineered hunter cells greatly expand and then persist in patients, allowing for long-term disease control. This allays previous concerns that infused cells only survive for a limited time. In the relatively short time that we've observed these patients, we have reason to believe that this treatment could become a viable therapy for their relapsed, treatment-resistant disease and we look forward to continuing to evaluate their long-term response."
Dr. Grupp will present this study during an oral presentation at 5 p.m. CST on Sunday, December 8, in La Nouvelle Ballroom C of the Ernest N. Morial Convention Center. 
Other People with the name "Grupp":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304